5 completed, 1 terminated, 1 unknown, 1 withdrawn. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Otitis: new trials by email Literature Review of Otitis trials Research Report on Otitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media Drug: OP0201 20mg, Drug: Placebo 0mg - Acute Otitis Media | Phase 1 | Completed | Novus Therapeutics, Inc | 24 | 2019-01-07 | 2019-12-05 |
| A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%, piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%, piperacillin 2% + tazobactam 0.25% - Otitis Media, Otorrhea | Phase 1 / Phase 2 | Terminated | Yuhan Corporation | 135 | 2016-06-01 | 2022-01-13 |
| Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol 0.1% Pazufloxacin Mesilate Ear Drops, 0.3% Pazufloxacin Mesilate Ear Drops, 0.5% Pazufloxacin Mesilate Ear Drops - Otitis Media | Phase 1 | Unknown | Lee's Pharmaceutical Limited | 32 | 2015-07-01 | 2015-10-30 |
| Pharmacokinetic Study of AL-60371 Otic Suspension in Pediatric Subjects Following Tympanostomy Tube Surgery AL-60371 otic suspension - Otitis Media | Phase 1 | Withdrawn | Alcon Research | 2014-11-01 | 2016-03-08 | |
| Trans-Middle-Ear Mucosal Gas Exchange Project 1, Specific Aim 1 6%CO2, 25%O2, balance N2, 6% CO2, 0%O2, balance N2, 20%CO2, 6%O2, balance N2 - Middle Ear Gas Exchange | Phase 1 | Completed | Cuneyt M. Alper | 16 | 2014-05-13 | 2019-02-19 |
| Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa 0.3% Ciprofloxacin Ear Drops, 0.3% Ciprofloxacin Foam Otic Cipro - Otitis Externa, Otorhinolaryngologic Diseases | Phase 1 / Phase 2 | Completed | Otic Pharma | 100 | 2009-05-01 | 2009-12-24 |
| Maternal Immunization To Prevent Infant Otitis Media PNCRM9, Placebo comparator - Otitis Media | Phase 1 / Phase 2 | Completed | National Institute on Deafness and Other Communication Disorders (NIDCD) | 153 | 2000-10-01 | 2008-02-18 |
| Vaccination for Middle Ear Infection Nontypeable Haemophilus influenzae - Otitis Media | Phase 1 | Completed | National Institute on Deafness and Other Communication Disorders (NIDCD) | 40 | 1997-05-01 | 2008-03-04 |
Otitis Media (6) · Ear Diseases (1) · Earache (1) · Otitis Externa (1) · Otorhinolaryngologic Diseases (1) · Tetanus (1)
Ear Diseases (7) · Otorhinolaryngologic Diseases (7) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Clostridium Infections (1) · Gram-Positive Bacterial Infections (1) · Infections (1) · Neurologic Manifestations (1) · Pain (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Ciprofloxacin (1) · Piperacillin (1) · Tazobactam (1) · ompP2 protein, Haemophilus influenzae (1)
National Institute on Deafness and Other Communication Disorders (NIDCD) (2) · Alcon Research (1) · Cuneyt M. Alper (1) · Lee's Pharmaceutical Limited (1) · Novus Therapeutics, Inc (1) · Otic Pharma (1) · Yuhan Corporation (1)
United States (4) · China (1) · Israel (1) · South Korea (1)
Celeste McClean, BS, MT (ASCP) (1) · Cuneyt M Alper, MD (1) · Patricia Ferrieri (1) · Weiguo Cue, MD (1) · Yehudah Roth, MD (1)
P50DC007667 (1)